Search results
Is IPSEN (IPSEY) Outperforming Other Medical Stocks This Year?
Zacks via Yahoo News· 1 year agoFor those looking to find strong Medical stocks, it is prudent to search for companies in the group...
Exelixis' (EXEL) Prostate Cancer Study Meets Primary Endpoint
Zacks via Yahoo News· 11 months agoExelixis, Inc. EXEL and partner Ipsen announced that the late-stage CONTACT-02 study achieved one of...
Why Is Exelixis (EXEL) Down 8.8% Since Last Earnings Report?
Zacks via Yahoo News· 2 years agoA month has gone by since the last earnings report for Exelixis (EXEL). Shares have lost about 8.8%...
Exelixis (EXEL) Late-Stage Study in Pancreatic Tumors Positive
Zacks via Yahoo News· 10 months agoExelixis' (EXEL) phase III CABINET study shows dramatic improvement in efficacy in advanced...
Exelixis (EXEL) Gains 30% YTD on Cabometyx, Pipeline Progress
Zacks via Yahoo News· 8 months agoExelixis (EXEL) lead drug Cabometyx maintains momentum on consistent demand. Efforts to develop...
Exelixis (EXEL) Q3 Earnings and Sales Miss, Annual View Updated
Zacks via Yahoo News· 8 months agoExelixis, Inc. EXEL reported earnings of 10 cents per share in the third quarter of 2023, which...
Exelixis (EXEL) to Post Q2 Earnings: What is in the Cards?
Zacks via Yahoo News· 2 years agoInvestors will likely focus on the demand for Cabometyx and pipeline updates when Exelixis (EXEL)...
Festival Lumière: Gender parity is making up for lost time at film festivals
Euronews via Yahoo News· 9 months agoMore women have won top prizes at historic film festivals in the last six years than in six decades....
San Sebastian High-Tech Startup Challenge Wins: Witscript and Hyperate.io Now Vie for Up to $530,000...
Variety via Yahoo News· 9 months agoWitscript and Hyperrate.io took home the prizes at San Sebastian’s 5th Zinemaldia Startup Challenge...
Epizyme (EPZM) Q2 Earnings Beat Estimates, Revenues Up Y/Y
Zacks via Yahoo News· 2 years agoEpizyme, Inc. EPZM incurred a loss of 21 cents per share in second-quarter 2022, narrower than the...